Myelodysplastic Syndromes Clinical Trials

74 studies are recruiting for myelodysplastic syndromes in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

   This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hemat…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Boston Children's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04024761 on ClinicalTrials.gov

2. Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

   The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MP…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06138587 on ClinicalTrials.gov

3. Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

   The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Medical University of South Carolina, Charleston, South Carolina

   Locations

   30 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT02074839 on ClinicalTrials.gov

4. Investigation of the Genetics of Hematologic Diseases

   The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings…

   Stage

   Not phased

   Ages

   Any age

   Site

   St. Jude Children's Research Hospital, Memphis, Tennessee

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT02720679 on ClinicalTrials.gov

5. A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

   To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05365035 on ClinicalTrials.gov

6. Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

   This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic synd…

   Stage

   Phase 2

   Ages

   0 to 39

   Site

   University of Florida, Gainesville, Florida

   Run by

   University of Florida

   See if you can join NCT05800210 on ClinicalTrials.gov

7. Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

   The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflamm…

   Stage

   EARLY_Phase 1

   Ages

   18 to 75

   Site

   Wilmot Cancer Institute, University of Rochester, Rochester, New York

   Run by

   Omar Aljitawi

   See if you can join NCT03964506 on ClinicalTrials.gov

8. A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

   The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. Participants will receive different doses of momelotinib to find the best dose by evaluating…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   GSK Investigational Site, Goodyear, Arizona

   Locations

   39 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06847867 on ClinicalTrials.gov

9. Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

   This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with severe renal impairment and cance…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson, Houston, Texas

   Locations

   21 in total

   Run by

   Taiho Oncology, Inc.

   See if you can join NCT04953897 on ClinicalTrials.gov

10. Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

    This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with moderate and se…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson, Houston, Texas

    Locations

    22 in total

    Run by

    Taiho Oncology, Inc.

    See if you can join NCT04953910 on ClinicalTrials.gov

11. 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

    Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are made. In bone marrow failure, the ability for bone marrow to make these cells is decreased. In myelodysplastic syndrome, this decreased bon…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio

    Run by

    Benjamin Tomlinson

    See if you can join NCT04187703 on ClinicalTrials.gov

12. Cord Blood Transplantation in Children and Young Adults With Blood Cancer

    The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.

    Stage

    Phase 2

    Ages

    Up to 26

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07566377 on ClinicalTrials.gov

13. Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

    The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) where they st…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Virginia, Charlottesville, Virginia

    Run by

    University of Virginia

    See if you can join NCT07270978 on ClinicalTrials.gov

14. Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

    Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    7 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT02269592 on ClinicalTrials.gov

15. A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

    Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (o…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Keck School of Medicine of USC, Los Angeles, California

    Locations

    71 in total

    Run by

    Taiho Oncology, Inc.

    See if you can join NCT04256317 on ClinicalTrials.gov

16. Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

    The goal of this interventional clinical trial is to evaluate the safety and tolerability of leflunomide in combination with decitabine as treatment for patients with relapsed or refractory myelodysplastic syndromes (R/R MDS). The main question this study aims to answer are to evaluate and estimate…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    West Virginia University Cancer Institute, Morgantown, West Virginia

    Run by

    West Virginia University

    See if you can join NCT06923488 on ClinicalTrials.gov

17. MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

    This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

    Stage

    Phase 2

    Ages

    2 to 75

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT07493538 on ClinicalTrials.gov

18. The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

    To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.

    Stage

    Not phased

    Ages

    18 to 120

    Site

    Wake Forest Baptist Health, Winston-Salem, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT01890486 on ClinicalTrials.gov

19. A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

    The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic sy…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic Arizona, Phoenix, Arizona

    Locations

    8 in total

    Run by

    Chordia Therapeutics, Inc.

    See if you can join NCT05732103 on ClinicalTrials.gov

20. UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

    Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation procedure. In such settings standard immune suppression strategies are avoided due to their myelosuppressive nature. Therefore those patients …

    Stage

    Phase 1

    Ages

    0 to 75

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06047886 on ClinicalTrials.gov

21. A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

    Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). Th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    8 in total

    Run by

    GluBio Therapeutics Inc.

    See if you can join NCT06146257 on ClinicalTrials.gov

22. Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

    This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT06502145 on ClinicalTrials.gov

23. Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

    This research is being done to evaluate effectiveness, safety, and tolerability of a study drug called momelotinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), MDS/MPN-not otherwise specified (MDS/MPN-NOS), MDS/MPN with neutrophilia (MDS/MPN-N), also called as atypi…

    Stage

    EARLY_Phase 1

    Ages

    18 to 100

    Site

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT07071155 on ClinicalTrials.gov

24. Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

    Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partial…

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    University of Kansas Cancer Center, Westwood, Kansas

    Locations

    2 in total

    Run by

    University of Kansas Medical Center

    See if you can join NCT03533816 on ClinicalTrials.gov

25. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Hoag Family Cancer Center, Newport Beach, California

    Locations

    104 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT04988555 on ClinicalTrials.gov